دورية أكاديمية
أعرض في EDS

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

التفاصيل البيبلوغرافية
العنوان: Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.
المؤلفون: Gomez GG; Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA., Wykosky J; Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA., Zanca C; Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA., Furnari FB; Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA., Cavenee WK; Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA.
المصدر: Cancer biology & medicine [Cancer Biol Med] 2013 Dec; Vol. 10 (4), pp. 192-205.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Chinese Anti-Cancer Association Country of Publication: China NLM ID: 101588850 Publication Model: Print Cited Medium: Print ISSN: 2095-3941 (Print) Linking ISSN: 20953941 NLM ISO Abbreviation: Cancer Biol Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Tianjin] : Chinese Anti-Cancer Association
مستخلص: Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor (EGFR) regulate cellular homeostatic processes. EGFR activates downstream signaling cascades that promote tumor cell survival, proliferation and migration. Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes. Consequently, concerted efforts have been mounted to develop therapeutic agents and strategies to effectively inhibit EGFR. However, limited therapeutic benefits to cancer patients have been derived from EGFR-targeted therapies. A well-documented obstacle to improved patient survival is the presence of EGFR-inhibitor resistant tumor cell variants within heterogeneous tumor cell masses. Here, we summarize the mechanisms by which tumors resist EGFR-targeted therapies and highlight the emerging role of microRNAs (miRs) as downstream effector molecules utilized by EGFR to promote tumor initiation, progression and that play a role in resistance to EGFR inhibitors. We also examine evidence supporting the utility of miRs as predictors of response to targeted therapies and novel therapeutic agents to circumvent EGFR-inhibitor resistance mechanisms.
References: Cancer Cell. 2010 Sep 14;18(3):282-93. (PMID: 20832755)
Cancer Res. 1990 Jul 1;50(13):3934-9. (PMID: 2354442)
Oncologist. 2002;7 Suppl 4:31-9. (PMID: 12202786)
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14240-5. (PMID: 21831840)
Clin Cancer Res. 2006 Jul 1;12(13):4103-11. (PMID: 16818711)
Nat Med. 2011 Dec 11;18(1):74-82. (PMID: 22157681)
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):5-8. (PMID: 20005451)
Curr Cancer Drug Targets. 2012 Mar;12(3):197-209. (PMID: 22268382)
Biomaterials. 2013 Nov;34(34):8690-707. (PMID: 23953842)
Nat Genet. 2009 Jul;41(7):843-8. (PMID: 19483683)
J Clin Neurosci. 2009 Jun;16(6):748-54. (PMID: 19324552)
Lab Invest. 2010 Feb;90(2):144-55. (PMID: 20048743)
Endocrinology. 1995 Jul;136(7):3163-72. (PMID: 7540549)
Br J Cancer. 2004 Aug 2;91(3):418-24. (PMID: 15238978)
Science. 2008 Apr 4;320(5872):97-100. (PMID: 18292307)
Genes Dev. 2002 Mar 15;16(6):720-8. (PMID: 11914277)
PLoS One. 2012;7(10):e47067. (PMID: 23115635)
Cell. 2007 Dec 14;131(6):1109-23. (PMID: 18083101)
Adv Exp Med Biol. 2013;774:77-101. (PMID: 23377969)
Cancer Res. 2005 Jan 1;65(1):338-48. (PMID: 15665312)
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3384-9. (PMID: 19211792)
J Clin Oncol. 2013 Sep 20;31(27):3335-41. (PMID: 23816963)
Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31. (PMID: 8052651)
Mol Carcinog. 2009 Jul;48(7):610-7. (PMID: 19058255)
Cancer Res. 2009 Oct 1;69(19):7569-76. (PMID: 19773441)
J Biol Chem. 1999 Mar 26;274(13):8900-9. (PMID: 10085134)
Genes Dev. 2010 Aug 15;24(16):1731-45. (PMID: 20713517)
Curr Biol. 2002 Apr 30;12(9):735-9. (PMID: 12007417)
Lancet Oncol. 2010 Aug;11(8):753-62. (PMID: 20619739)
Science. 2007 Oct 12;318(5848):287-90. (PMID: 17872411)
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4339-44. (PMID: 23440206)
Nature. 2009 Jul 23;460(7254):529-33. (PMID: 19626115)
Oncologist. 2012;17(6):823-9. (PMID: 22584434)
Cancer Res. 1988 Dec 1;48(23):6753-7. (PMID: 2460228)
Pharmacogenomics J. 2010 Oct;10(5):458-64. (PMID: 20177422)
Cancer Cell. 2005 Apr;7(4):301-11. (PMID: 15837620)
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90. (PMID: 19597153)
Clin Cancer Res. 2006 Oct 1;12(19):5764-9. (PMID: 17020982)
PLoS One. 2012;7(6):e39520. (PMID: 22761812)
Oncogene. 2013 Aug 15;32(33):3846-56. (PMID: 23045285)
Carcinogenesis. 2009 Jun;30(6):1003-7. (PMID: 19380522)
Expert Rev Vaccines. 2012 Feb;11(2):133-44. (PMID: 22309662)
Mol Cell Biol. 2004 Aug;24(16):7059-71. (PMID: 15282306)
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9. (PMID: 9576951)
Nat Med. 2012 Mar 04;18(4):529-37. (PMID: 22388088)
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81. (PMID: 17255257)
J Clin Oncol. 2008 Apr 1;26(10):1626-34. (PMID: 18316791)
Cell Death Differ. 2006 Jun;13(6):1027-36. (PMID: 16557269)
Neoplasia. 2013 May;15(5):544-53. (PMID: 23633926)
Clin Cancer Res. 2007 Mar 1;13(5):1552-61. (PMID: 17332301)
Cell. 2005 Mar 11;120(5):635-47. (PMID: 15766527)
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. (PMID: 17360479)
Annu Rev Biochem. 1979;48:193-216. (PMID: 382984)
Cancer Res. 2010 Nov 1;70(21):8822-31. (PMID: 20978205)
Cancer Res. 2006 Apr 15;66(8):3992-5. (PMID: 16618717)
Sci Rep. 2013;3:2459. (PMID: 23963283)
Nature. 2000 Nov 2;408(6808):86-9. (PMID: 11081512)
Toxicol Pathol. 2011 Jan;39(1):158-66. (PMID: 21078918)
Pharmacogenet Genomics. 2013 Mar;23(3):142-7. (PMID: 23324806)
Int J Med Sci. 2008 Jul 11;5(4):209-17. (PMID: 18645621)
Cancer Res. 2004 Jun 1;64(11):3753-6. (PMID: 15172979)
Radiother Oncol. 2011 Oct;101(1):171-6. (PMID: 21676478)
Science. 2001 Oct 26;294(5543):853-8. (PMID: 11679670)
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. (PMID: 15329413)
N Engl J Med. 2008 Sep 11;359(11):1116-27. (PMID: 18784101)
Cell. 1993 Dec 3;75(5):843-54. (PMID: 8252621)
J Biol Chem. 2009 Feb 27;284(9):5731-41. (PMID: 19073608)
Oncogene. 2009 Jan 8;28(1):73-84. (PMID: 18850008)
Cancer Res. 1999 Mar 15;59(6):1236-43. (PMID: 10096554)
Exp Cell Res. 2006 Sep 10;312(15):2778-90. (PMID: 16806168)
Cancer Res. 2011 Feb 1;71(3):852-61. (PMID: 21156648)
Cell Regul. 1991 May;2(5):337-45. (PMID: 1716463)
Nat Rev Cancer. 2007 Mar;7(3):169-81. (PMID: 17318210)
Oncol Lett. 2010 Nov;1(6):1045-1047. (PMID: 22870110)
Breast Cancer Res Treat. 2006 Feb;95(3):211-8. (PMID: 16261406)
Biochem Biophys Res Commun. 2013 Jan 11;430(2):706-10. (PMID: 23206698)
Cancer Res. 2012 Nov 1;72(21):5576-87. (PMID: 22964582)
J Clin Oncol. 2006 Oct 20;24(30):4914-21. (PMID: 17050875)
J Clin Oncol. 2007 May 1;25(13):1658-64. (PMID: 17470858)
J Clin Oncol. 2010 Nov 1;28(31):4722-9. (PMID: 20921459)
Cell. 2001 Jul 13;106(1):23-34. (PMID: 11461699)
Mol Cell. 2007 Jun 8;26(5):731-43. (PMID: 17540598)
Cell Cycle. 2010 Mar 15;9(6):1031-6. (PMID: 20190569)
Nucleic Acids Res. 2012 Jan;40(1):438-48. (PMID: 21914725)
Cell. 2007 Jul 13;130(1):89-100. (PMID: 17599402)
Nat Cell Biol. 2010 Mar;12(3):247-56. (PMID: 20173740)
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. (PMID: 18093943)
Oncogene. 2008 Jun 26;27(28):3944-56. (PMID: 18297114)
Cancer Res. 1997 Sep 15;57(18):4130-40. (PMID: 9307304)
PLoS One. 2013 Apr 10;8(4):e61054. (PMID: 23593387)
Eur J Cancer. 2010 Jan;46(2):298-311. (PMID: 19948396)
PLoS Med. 2006 Dec;3(12):e485. (PMID: 17177598)
Science. 2004 Jun 4;304(5676):1497-500. (PMID: 15118125)
Oncogene. 2008 Aug 7;27(34):4702-11. (PMID: 18408761)
Br J Cancer. 2006 Jan 30;94(2):184-8. (PMID: 16434982)
Nat Rev Clin Oncol. 2010 Sep;7(9):493-507. (PMID: 20551942)
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8. (PMID: 11597398)
Clin Cancer Res. 2013 Sep 15;19(18):5027-38. (PMID: 23888072)
Cancer Res. 2008 May 15;68(10):3566-72. (PMID: 18483236)
Clin Cancer Res. 2005 Aug 15;11(16):5856-62. (PMID: 16115926)
Mol Biotechnol. 2013 Jul;54(3):913-9. (PMID: 23277327)
Clin Cancer Res. 1997 Apr;3(4):515-22. (PMID: 9815714)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. (PMID: 12434020)
RNA. 2003 Feb;9(2):175-9. (PMID: 12554859)
J Clin Oncol. 2005 May 10;23(14):3227-34. (PMID: 15886310)
J Biol Chem. 2009 Jul 3;284(27):18515-24. (PMID: 19419954)
PLoS One. 2012;7(10):e47449. (PMID: 23077620)
Hepatology. 2012 Jun;55(6):1852-62. (PMID: 22234835)
Cancer Res. 2008 Dec 15;68(24):10128-36. (PMID: 19074879)
Cancer Res. 2008 Oct 15;68(20):8535-40. (PMID: 18922928)
Genes Dev. 2012 Apr 15;26(8):756-84. (PMID: 22508724)
Clin Cancer Res. 2013 Jan 1;19(1):279-90. (PMID: 23091115)
Nat Cell Biol. 2001 Sep;3(9):802-8. (PMID: 11533659)
Cancer Res. 2001 Feb 1;61(3):842-7. (PMID: 11221866)
Hepatology. 1991 Jan;13(1):15-20. (PMID: 1988335)
Cancer Res. 2001 Jul 15;61(14):5349-54. (PMID: 11454673)
Genes Dev. 2004 Dec 15;18(24):3016-27. (PMID: 15574589)
Clin Cancer Res. 2010 Feb 15;16(4):1119-28. (PMID: 20145172)
Nat Cell Biol. 2006 Dec;8(12):1359-68. (PMID: 17115032)
Cell. 2005 Dec 29;123(7):1267-77. (PMID: 16377567)
Nat Rev Genet. 2009 Oct;10(10):704-14. (PMID: 19763153)
Sci Signal. 2009 Sep 08;2(87):re6. (PMID: 19738203)
Genes Dev. 2003 Dec 15;17(24):3011-6. (PMID: 14681208)
J Cell Mol Med. 2009 Jan;13(1):39-53. (PMID: 19175699)
Science. 2007 May 18;316(5827):1039-43. (PMID: 17463250)
J Neurooncol. 1994;22(3):201-7. (PMID: 7760096)
Nature. 2007 Jun 28;447(7148):1130-4. (PMID: 17554337)
Oncogene. 2010 May 6;29(18):2638-48. (PMID: 20154725)
N Engl J Med. 2004 Jul 22;351(4):337-45. (PMID: 15269313)
N Engl J Med. 2004 May 20;350(21):2129-39. (PMID: 15118073)
Oncogene. 2011 Jan 20;30(3):275-86. (PMID: 20956945)
Cancer Res. 2005 Jul 15;65(14):6029-33. (PMID: 16024602)
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61. (PMID: 18768788)
Chin J Cancer. 2011 Jan;30(1):5-12. (PMID: 21192840)
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13092-7. (PMID: 17670948)
Clin Cancer Res. 2009 Nov 1;15(21):6484-9. (PMID: 19861462)
N Engl J Med. 2005 Nov 10;353(19):2012-24. (PMID: 16282176)
Cancer Res. 2000 Mar 1;60(5):1383-7. (PMID: 10728703)
Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4. (PMID: 8864278)
J Neuropathol Exp Neurol. 1992 Jan;51(1):84-90. (PMID: 1311022)
Cancer Res. 2008 Nov 15;68(22):9479-87. (PMID: 19010923)
J Mol Histol. 2013 Dec;44(6):669-77. (PMID: 23793934)
Cancer Prev Res (Phila). 2012 Feb;5(2):248-59. (PMID: 21982874)
Br J Cancer. 1992 Aug;66(2):373-85. (PMID: 1503912)
Blood. 2009 Apr 16;113(16):3801-8. (PMID: 18941118)
Nat Rev Cancer. 2006 Nov;6(11):857-66. (PMID: 17060945)
J Neurooncol. 2011 Mar;102(1):19-24. (PMID: 20607356)
Brain Tumor Pathol. 2004;21(2):53-6. (PMID: 15700833)
RNA. 2008 Jan;14(1):35-42. (PMID: 18025253)
J Biol Chem. 2011 May 27;286(21):19127-37. (PMID: 21471222)
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10144-9. (PMID: 21646541)
BMC Genomics. 2010 May 07;11:288. (PMID: 20459673)
معلومات مُعتمدة: P01 CA095616 United States CA NCI NIH HHS; R01 NS080939 United States NS NINDS NIH HHS
فهرسة مساهمة: Keywords: Epidermal growth factor receptor; microRNA; therapeutic resistance; tyrosine kinase inhibitors
تواريخ الأحداث: Date Created: 20131219 Date Completed: 20140624 Latest Revision: 20240413
رمز التحديث: 20240413
مُعرف محوري في PubMed: PMC3860350
DOI: 10.7497/j.issn.2095-3941.2013.04.003
PMID: 24349829
قاعدة البيانات: MEDLINE
الوصف
تدمد:2095-3941
DOI:10.7497/j.issn.2095-3941.2013.04.003